RxDoctor Payments Data

Amarjit Singh, MD

Internal Medicine · South Richmond Hill, NYNPI 1801951280

Payments from drug & device makers

$2,844in general payments, 2019–2025

Across 123 payments — averaging $23.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$631
  • Bayer$416
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$276
  • Merck$237
  • Boehringer Ingelheim$195
  • Lilly USA, LLC$146
  • plus $944 from 17 others

What the payments were for

  • Food & beverage$2,833100%
  • Education$100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,844 in reported general payments places this provider in the 80th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$103,345
Medicare patients
79
Services billed
1,270

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate110$134,793
TrulicityDulaglutide76$130,432
FarxigaDapagliflozin Propanediol76$79,514
JanumetSitagliptin Phos/Metformin Hcl61$78,721
JardianceEmpagliflozin53$78,503
EliquisApixaban57$74,135
EntrestoSacubitril/Valsartan44$62,617
OzempicSemaglutide32$58,548
MounjaroTirzepatide30$46,176
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog45$27,990
XareltoRivaroxaban15$25,400
Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp48$12,225
VascepaIcosapent Ethyl23$8,460
Atorvastatin Calcium520$6,632
Metoprolol Succinate335$6,279

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia, Janumet$237$213,515171 claims
Lilly USA, LLCTrulicity, Mounjaro$146$176,608106 claims
AstraZenecaFarxiga$631$79,51476 claims
Boehringer IngelheimJardiance$195$78,50353 claims
PfizerEliquis$74$74,13557 claims
NovartisEntresto$24$62,61744 claims
Novo NordiskOzempic$125$58,54832 claims
Johnson & JohnsonXarelto$20$25,40015 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in South Richmond Hill

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →